Pain is a symptom, fundamentally results from any injury, infection, disorder or disease. Globally more than 1.5 billion people suffer from different types of pain and among all, lower back pain, neck pain, headache and facial pain are most common. Unlike acute pain which is temporary and relieved when underlying cause is healed, chronic pain in general lasts for longer period of time. Management of pain is accomplished with the various treatment by using drug therapy, physical therapy, biofeedback and other treatments.

The non-opioid pain patch is kind of a treatment for pain relief. The pain patch, when placed on painful area releases its medicine content through skin surface and inhibit the pain signal transfer. The patches can be customized as per the applied area. To counteract the opioid abuse, newer, innovative and more effective non-opioid pain patches are getting developed which in turn drive the non-opioid pain patch market growth.

Rising opioid abuse is the major concern as only in U.S. more than 20,000 death has been recorded resulting from opioid overdose. Along with, rising opioid abuse, the harmful side effects of opioids drive the usage of non-opioid pain patch and drive its market. The increasing trend of chronic pain contributes growth of the non-opioid pain patch market. The non-opioid pain patch market is still growing as many of its products are under clinical trial. Teikoku Pharma USA, Inc. declared their recent innovation dexmedetomidine transdermal non-opioid pain patch for post-surgical pain treatment which is still under clinical trial and expected to provide effective result in pain management. However, the lower adoption rate of non-opioid pain patch in contrast to drugs, poses some challenges to the growth of non-opioid pain patch market.

The purpose of this research study titled ‘Non-Opioid Pain Patch Market - Growth, Future Prospects, and Competitive Analysis, 2017 – 2025’ is to provide investors, developers, company executives and industry participants with in-depth analysis to allow them to take strategic initiatives and decisions related to the prospects in the global non-opioid pain patch market. This report presents and analyzes the major trends prevalent in the global non-opioid pain patch market and the market size and forecast.

This report categorizes the global non-opioid pain patch market in terms of patch type, distribution channel and geographical distribution. On the basis of patch type, the non-opioid pain patch market is classified as follows:

• Lidocaine Patches
• Diclofenac Patches
• Capsaicin Patches
• Methyl Salicylate Patches
• Others

Based on the distribution channel the non-opioid pain patch market is categorized as:

• Hospital pharmacy
• Retail pharmacy/Independent pharmacy
• E-commerce/ Online pharmacy

Geographically, the non-opioid pain patch market is best understood by segmenting the market into five major regions and chief region level markets as follows:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • Rest of Asia Pacific
• Latin America Middle East and Africa
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa

The market size and forecast of each considered geographical market is presented for the period 2015-2025 along with CAGRs for the forecast period 2017-2025 in this study and are further cross-sectional presented in terms of type of patches, distribution channel type and constituent region/country level markets.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global non-opioid pain patch market. Competition assessment tools such as, major agreements, partnerships and collaborations, market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the non-opioid pain patch market. The key players profiled in this report are Teh Seng Pharmaceutical Mfg. Co., Ltd., Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd., Allergan, Pfizer, Inc., Hisamitsu Pharmaceutical Co. Inc., GlaxoSmithKline plc., Mylan N.V., IBSA Institut Biochimque SA, Inc., Acorda Therapeutics and others.

Transdermal drug delivery is the best alternative of oral drug delivery. This non-invasive procedure provides better patient outcome with lesser adverse effects.

Based on the type of patches, the non-opioid pain patch market has been categorized as below:

• Lidocaine Patches
• Diclofenac Patches
• Capsaicin Patches
• Methyl Salicylate Patches
• Others

Lidocaine patch is a non-opioid, applied to healthy skin. This patch is used to treat neuropathic pain generally from post-herpetic neuralgia and it is also useful for the treatment of diabetic neuropathy or HIV related neuropathy. Lidoderm was the first Lidocaine patch which received FDA approval. Lidocaine patch market is expected to be the largest and estimated to grow more in near future. The safety, fewer risk and lesser chances of side effects contribute to the growth of its market.

Methyl salicylate patch is used to treat the pain caused by arthritis, strain or sprain. Salonpas is the first and only FDA approved over-the-counter methyl salicylate pain patch. Capsaicin patches helps to resolve muscle or joint pains and Diclofenac patches work by blocking the pain producing agent for the treatment of pain from minor strain, bruise or injury.

Although there are some adverse effects associated with the non-opioid patches like allergic reaction, hives, redness, blisters, shortness of breathing etc. however benefits of customization of patches, easy administration, fewer doses, and better patient outcome attribute the growth of the non-opioid pain patch market.

Depending on the distribution channel the non-opioid pain patch market is segmented into below categories:

• Hospital pharmacy
• Retail pharmacy/Independent pharmacy
• E-commerce/Online pharmacy

The hospital pharmacy is predicted to contribute to the maximum growth of the non-opioid pain patch market, whereas the retail pharmacy and e-commerce are expected to face major growth in forecasting years due to extensive discount and easy availability of products. In case of online pharmacy, the option of free delivery draws the attention of public, hence expected to face lucrative growth in upcoming years.

The global non-opioid pain patch market regionally is cumulative to North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

North America is anticipated to dominate the non-opioid pain patch market followed by Europe. As per the study of National Institutes of Health’s National Center for Complementary and Integrative Health (NCCIH), more than 50 million people in America suffer from chronic pain. Pain is a serious health issue globally, in which $560-635 Bn USD is spent annually for the treatment only in the U.S. This increasing incidence of severe pain along with the public health awareness attribute to the dominance of North American region.  More than 2 million people substance abuse disorder using prescription opioids and around 20,000 people died from opioid overdose in 2015. This rate of opioid abuse shift the trend of pain management towards non-opioid pain patch. Research on innovative and effective product development for pain management drive the non-opioid pain patch market in North-America and European region. The prevalence of post-herpetic neuralgia is around 144,000 in U.S., and the associated pain is difficult to treat with oral drugs which drive more usage of Lidocaine patch and fuel its growth. The huge number of population suffering from pain disorders, developing healthcare infrastructure, cost-effectiveness fuel the growth of non-opioid pain patch market in Asia-Pacific region and it is expected to face substantial growth in upcoming periods due to the growing trend of health awareness in public.

The detailed regional classification of the global non-opioid pain patch market is as follows:

• North America (U.S. & Canada)
• Europe (Germany, U.K., France, Spain, Italy and Rest of Europe)
• Asia Pacific (China, India, Japan and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East and Africa (GCC and Rest of Middle East and Africa)